DexCom (NASDAQ:DXCM) Stock Rating Upgraded by Mizuho

DexCom (NASDAQ:DXCM - Get Free Report) was upgraded by Mizuho to a "strong-buy" rating in a research note issued on Wednesday,Zacks.com reports.

A number of other brokerages have also recently weighed in on DXCM. Canaccord Genuity Group raised their price target on DexCom from $99.00 to $103.00 and gave the company a "buy" rating in a research report on Friday, February 14th. Baird R W upgraded shares of DexCom from a "hold" rating to a "strong-buy" rating in a research report on Thursday, January 16th. Redburn Atlantic raised shares of DexCom from a "neutral" rating to a "buy" rating and upped their price target for the company from $85.00 to $115.00 in a report on Monday, February 3rd. Citigroup raised their price objective on shares of DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a research note on Tuesday, March 4th. Finally, Wells Fargo & Company reiterated an "overweight" rating on shares of DexCom in a research report on Saturday, March 8th. Five equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, DexCom presently has an average rating of "Moderate Buy" and an average price target of $99.00.

DexCom Price Performance

Shares of DXCM traded up $1.84 during mid-day trading on Wednesday, hitting $69.23. The company's stock had a trading volume of 4,613,407 shares, compared to its average volume of 4,194,902. The firm has a 50-day simple moving average of $76.49 and a 200 day simple moving average of $76.68. DexCom has a 1-year low of $57.52 and a 1-year high of $139.24. The firm has a market capitalization of $27.15 billion, a P/E ratio of 48.41, a P/E/G ratio of 2.30 and a beta of 1.50. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59.

Remove Ads

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Analysts predict that DexCom will post 2.03 EPS for the current fiscal year.

Insider Buying and Selling

In other DexCom news, EVP Jereme M. Sylvain sold 2,090 shares of the company's stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the transaction, the executive vice president now owns 83,526 shares in the company, valued at $7,259,244.66. This represents a 2.44 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Jacob Steven Leach sold 2,634 shares of DexCom stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $228,920.94. Following the sale, the chief operating officer now owns 268,644 shares in the company, valued at $23,347,850.04. This represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 105,009 shares of company stock valued at $8,044,178. Company insiders own 0.30% of the company's stock.

Hedge Funds Weigh In On DexCom

A number of institutional investors have recently added to or reduced their stakes in DXCM. Versant Capital Management Inc acquired a new position in shares of DexCom in the fourth quarter worth about $25,000. Private Trust Co. NA raised its position in shares of DexCom by 266.3% in the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after purchasing an additional 245 shares in the last quarter. Optiver Holding B.V. purchased a new position in shares of DexCom during the 4th quarter valued at approximately $33,000. TD Private Client Wealth LLC grew its position in shares of DexCom by 62.8% during the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after buying an additional 167 shares in the last quarter. Finally, Larson Financial Group LLC boosted its stake in DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after acquiring an additional 137 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company's stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.